grail
-
In blood tests for early cancer detection, low false-positive rates can be a big deal
In data at the ASCO meeting last week, Grail showed a 1 percent false-positive rate. While that number seems likely to go down, even such a low rate can make a significant difference for patients.
-
Grail’s liquid biopsy test shows high sensitivity in early cancer detection
The company plans to present early data in a poster on Saturday showing no more than 1 percent of tests generated false-positive results across 12 solid tumor and blood cancers.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Biopharma 1H18 Series A investment exceeds funding for all of 2017
Investment could be called frothy, but hasn’t reached bubble territory yet, SVB report author says.
-
The 10 largest biotech and devices VC investments in Q2
The most recent MoneyTree report from PwC and CB Insights highlights the biggest biotech-related and medical devices VC deals in Q2, which include investments in companies like Grail, Allogene Therapeutics, RefleXion Medical and Mevion Medical Systems.
-
Billion-dollar cancer detection startup Grail names new CEO with commercial chops
After the surprise departure of its founding CEO in August, Illumina spin-out Grail has named Roche/Genentech’s Global Head of Clinical Operations Jennifer Cook as its new leader.
-
Startups, Devices & Diagnostics
In an era of mega-rounds, Roivant Sciences still makes a splash with $1.1B haul
Billion-dollar private venture capital rounds are apparently now a “thing.” Roivant sealed the deal on Wednesday, following a multi-year trend towards bigger investment rounds in the life sciences.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
Grail’s high profile CEO steps down after 18-month tenure
Illumina spin-out Grail revealed Wednesday that Jeff Huber is stepping down as CEO of the billion-dollar early cancer detection startup.
-
Healthcare is looking to the tech world for recruitment purposes
Providence St. Joseph Health recently hired Microsoft executive Venkat Bhamidipati as CFO. His appointment points to a trend of healthcare organizations eyeing the tech sector for new talent.
-
With $360M in new financing, Guardant Health prepares to sequence one million cancer patients
Guardant Health has unveiled an ambitious five-year plan to sequence tumor DNA from one million cancer patients. Dubbed “Guardant 1 million,” the push will be financed with $360 million in new financing from a broad syndicate of investors.
-
Grail initiates massive multicenter breast cancer study
The results of the study will serve as a baseline measure for detecting breast cancer in the blood and inform the development of Grail’s pan-cancer screening test.
-
Report: Digital health startups raise $2.5B in Q1 even as deal volume declines to six-year low
For the first time, population health startups attracted more investment than other digital health subsectors,
-
Behind Grail, Illumina’s billion-dollar diagnostics startup
With a billion dollars in private financing and a test projected to generate a terabyte of data per person, Grail has seeded a new category of diagnostics and Big Data. Despite this, the company story shared by CEO Jeff Huber is mostly about people.